The free Hope Flies Health Series Webinar: Research Connecting Parkinson’s Disease and Mitochondrial Disease is scheduled for 1 p.m. Eastern Standard Time on Wednesday, April 6. The event is hosted by the Foundation for Mitochondrial Medicine (FMM) and partners Michael J. Fox Foundation (MJFF), Wilkins Parkinson’s Foundation and…
News
mPower, a Parkinson’s disease (PD) iPhone app developed by Sage Bionetworks and a team of neurologists at the University of Rochester Medical Center (URMC), marked the first year of its release by being highlighted in Apple Inc.’s “Loop You In” special product launch event on March 21, 2016.
Patients with rosacea may be at an increased risk of new-onset Parkinson’s disease, according to a Danish population study, “Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study,” published in JAMA Neurology. Rosacea is a common chronic inflammatory skin condition characterized…
3-D ‘Scaffolds’ Supporting Healthy Neurons Offer New Stem Cell-Treatment Approach for Parkinson’s
Rutgers and Stanford University researchers have developed 3-D “scaffolds,” or fibers, that can support healthy and high-functioning human neurons derived from adult stem cells, which can be transplanted to the brain to replace diseased neurons. The technology represents a possible new therapeutic strategy for numerous neurological conditions, including Parkinson’s and Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple…
Multinational research-based biopharmaceutical company AbbVie‘s product DUOPA is a fresh approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations that afflict people with advanced Parkinson’s disease. A researcher, in an exclusive interview with Parkinson’s News Today at the recent 10th World Congress on…
That the formation of alpha-synuclein aggregates, formed by misfolded forms of the protein, is somehow linked to Parkinson’s disease development is a fact few would dispute. Whether preventing the formation, or increasing the clearance of these protein masses, possibly by vaccination, as a viable approach to treatment is, however, a…
Cynapsus Therapeutics, currently conducting a pivotal Phase 3 clinical study of its sublingual formulation of apomorphine to treat “OFF” episodes in Parkinson’s disease (PD), is teaming up with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for a sub-study that will use wearable technology to gather and analyze…
The 10th World Congress on Controversies in Neurology (CONy), now taking place in Lisbon, Portugal, is hosting international experts in the field, and serving as a platform for the comparison of experimental clinical and basic data in a range of diseases. The congress also offers the opportunity for debate on unresolved scientific issues. Research into…
Emory University researchers, investigating the role of dopamine in the regulation of vocal learning through auditory feedback, observed that reducing this neurotransmitter in a specific brain area, the basal ganglia, considerably impairs learning. The study, in songbirds called Bengalese finches, further illuminate the role of dopamine in vocal behavior, and is relevant to Parkinson’s disease,…
For the first time, researchers have identified the point at which alpha-synuclein – the protein whose aggregation leads to Parkinson’s disease – becomes toxic. The findings, published in the journal PNAS, shed new light on the toxicity processes leading to disease development and might provide clues in the…
Recent Posts
- Looking back at the changing roles and relationships in Parkinson’s
- Lab-made small molecule may help slow brain disease progression
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China